Unaudited Financial Results of the Company for the quarter ended June 30, 2026

Neuland Laboratories Limited /{ neuland 11th floor (5th level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CONTACT 040 67611600 / 67611700 neuland@neulandlabs.com neulandlabs.com August 5, 2026 BSE Limited The National Stock !Exchange of India Ltd Phiroze JeejeebhoyTowers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai - 400 001 Bandra Kurla Complex Sandra (E), Mumbai - 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Outcome of Board Meeting Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations&. Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. August 5, 2026, have considered and approved the following: A. Financial Results Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026. A copy of the Unaudited Financial Results for the quarter ended June 30, 2026, together with the limited review reports (Standalone & Consolidated) by the Statutory Auditors of the Company are enclosed herewith. B. Execution of deed of Corporate Guarantee for~ 40 crores in favour of Gland Pharma Limited in connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The requisite details are as under: Particulars Details Name of party for which guarantee Given Gland Pharma Limited Whether the promoter/ promoter group have No, the promoter/ promoter group do not have any any interest in this transaction? If yes, nature interest in this transaction of interest and details thereof and whether the same is done at "arm's length"; Brief details of such guarantee viz. brief details The Company will be executing an irrevocable, of agreement entered (if any) including unconditional and continuing Corporate Guarantee significant terms and conditions, including of Rs. 40 crores in favour of Gland Pharma Limited in amount of guarantee; connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited. Under the Loan Licence Agreement, Gland Pharma Limited has agreed to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The Corporate Guarantee secures the due payment and performance by the Company of its obligations under the Loan Licence Agreement. Impact of such guarantees or indemnity or There is no immediate impact on the financials of the surety on listed entity Company. The corporate guarantee ree._resents a contingent liability for the Company. A Press Release on the above Is enclosed as Annexure A REGISTERED OFFICE: 11th floor (5th level), Phoenix IVY Building, Plot No.573A-llI, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, lndlll. C11II No. L85195TG1984PLC004393 neuland C. Enhancement of manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The requisite details are as under: a. Existing Capacity (Unit 1) 376.5 KL b. Existing Capacity Utilization 91% c. Proposed Capacity Addition 18 KL d. Period within which the proposed 6-7 Months capacity is to be added e. Investment required , 39.8 crores (incl GST) f. Mode offinancing Through internal ac:cruals g. Rationale To maintain and cater to the growing demand of our customers The meeting of Board of Directors of the Company commenced at 10:00 a.m. and concluded at 3.42 p.m. The above information will also be available on the website of the Company at www.neulandlabs.com. This is for your information and records. Thanking you, Yours Sincerely, For Neuland LaboratQries Limited () -1-> Sarada Bhamidipati VJ Company Secretary' , ·: ·C Encl: As above MSKA & Associates LLP 1101 /B, Manjeera Trinity Corporate JNTU-Hitech City Road, Kukatpally (Formerly known as MS K A & Associates) Telangana, Hyderabad 500072, INDIA Chartered Accountants Independent Auditor's Review Report on consolidated unaudited financial results of Neuland Laboratories Limited for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Neuland Laboratories Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Neuland Laboratories Limited ("the Holding Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations"). 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. No Name of the Entity Relationship w;th the Holdinsz Comoanv 1 Neuland Laboratories K.K., Japan Wholly Owned Subsidiarv 2 Neuland Laboratories Inc. USA Wholly owned Subsidiarv 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbal-400063, Maharashtra, lndfa Tel: ~91 22 6974 0200 I LLPIN: ACT-3789 Ahmedabad I Bengaluru I Chandigarh I Cheonai I Coimbatore I Goa I Gurugram I Kochi I Kolkata I Mumbai I Pune www.mska in MSKA Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants 6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 606.5 [Showing first 8,000 characters — download PDF for full document]